Aucatzyl
Prescribing Information
Adverse Event Reporting
Autolus Assist

AUCATZYL: An additional treatment option for a broad range of patients with (R/R) B-ALL1,2

AUCATZYL is a CAR-T designed with next-generation CAT19 binding technology to mimic physiologic T-cell activation1-3
Indication

AUCATZYL is indicated for the treatment of adult patients (≥18 years) with relapsed or refactory B-cell precursor acute lymphoblastic leukarmia.1

For referring haematologists

Next-gen CAR-T

Discover the unique mechanism of action of AUCATZYL.

Clinical data

Explore the efficacy and safety profile of AUCATZYL from the pivotal FELIX trial.

Patient eligibility

Find out if your patients may be eligible for AUCATZYL treatment.

Support and resources

Learn how the Autolus team can support you and your patients.

For treating haematologists

Clinical data

Explore the efficacy and safety profile of AUCATZYL from the pivotal FELIX trial.

Process and administration

Learn more about tumour-guided split dosing and how to administer AUCATZYL.

Support and resources

Learn how the Autolus team can support you and your patients.

Treatment centres

Locate your nearest centre accepting patient referrals 
for AUCATZYL.

About Autolus

Discover our story and the ways we can partner with you.

Stay updated

Sign up to receive the latest news and product updates from Autolus.

Receive key updates

By clicking ‘Receive key updates’ you’re confirming that you agree with our Terms and conditions.

Indication

Aucatzyl is indicated for the treatment of adult patients (≥18 years) with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia.1

NICE Reimbursement

NICE recommends AUCATZYL to treat relapsed or refractory B-cell precursor acute lymphoblastic leukaemia in people aged ≥26 years in England, Wales and Northern Ireland.4,5

B-ALL=B-cell precursor acute lymphoblastic leukaemia; CAR=chimeric antigen receptor, NICE=National Institute for Health and Care Excellence. R/R=relapsed/refractory.

  1. Summary of Product Characteristics, Aucatzyl 2025.

  2. Roddie C, et al. Obecabtagene autoleucel in adults with B-cell acute lymphoblastic leukemia. N Engl J Med. 2024;391(23):2219–2230.

  3. Ghorashian S, et al. Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR. Nat Med. 2019;25:1408–1414.

  4. NICE. Obecabtagene autoleucel for treating relapsed or refractory B-cell precursor acute lymphoblastic leukaemia. Issued December 2025. Accessed March 2026. https://www.nice.org.uk/guidance/ta1116/resources/obecabtagene-autoleucel-for-treating-relapsed-or-refractory-bcell-precursor-acute-lymphoblastic-leukaemia-pdf-2973530453903557.

  5. AWTTC. obecabtagene autoleucel (Aucatzyl®). Issued November 2025. Accessed March 2026. https://awttc.nhs.wales/accessing-medicines/medicine-recommendations/obecabtagene-autoleucel-aucatzyl/.

April 2026 | UK-AUC-0177